Payment overview · 2025
General Payments
$329.80
3 reported records · 3 companies
Healthcare provider profile · identity verified
Andrew S Mccraw, MD
Allopathic & Osteopathic Physicians|Family Medicine · SIMPSONVILLE, SC · NPI 1992762611
Verified facts
What the public records show
CMS Open Payments records show Andrew S Mccraw, MD received $329.80 in general payments during 2025 across 3 reported records.
bioMerieux Inc accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| bioMerieux Inc | Unresolved — no canonical attribution shown | $168.11 | 51.0% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $148.08 | 44.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.61 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.80 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FilmArray Torch Module Normalized: filmarray torch module |
Device | bioMerieux Inc | $168.11 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 367 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 358 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 346 | 88 |
| Lisinopril | Lisinopril | 283 | 85 |
| Metformin Hcl | Metformin Hcl | 279 | 73 |
| Omeprazole | Omeprazole | 213 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 56 |
| Meloxicam | Meloxicam | 180 | 57 |
| Simvastatin | Simvastatin | 154 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 49 |
| Allopurinol | Allopurinol | 140 | 39 |
| Montelukast Sodium | Montelukast Sodium | 139 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 31 |
| Ozempic | Semaglutide | 118 | 20 |
| Losartan Potassium | Losartan Potassium | 113 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 104 | 78 |
| Gabapentin | Gabapentin | 103 | 30 |
| Ezetimibe | Ezetimibe | 97 | 20 |
| Carvedilol | Carvedilol | 84 | 24 |
| Januvia | Sitagliptin Phosphate | 84 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 17 |
| Prednisone | Prednisone | 80 | 54 |
| Jardiance | Empagliflozin | 79 | 17 |
| Furosemide | Furosemide | 74 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 24 |
| Sertraline Hcl | Sertraline Hcl | 70 | 19 |
| Temazepam | Temazepam | 66 | suppressed |
| Spironolactone | Spironolactone | 65 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 20 |
| Trazodone Hcl | Trazodone Hcl | 64 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 14 |
| Xarelto | Rivaroxaban | 55 | 12 |
| Famotidine | Famotidine | 54 | 16 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Dutasteride | Dutasteride | 51 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 14 |
| Azelastine Hcl | Azelastine Hcl | 50 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 16 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 19 |
| Eliquis | Apixaban | 42 | 16 |
| Potassium Chloride | Potassium Chloride | 42 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | 11 |
| Cefdinir | Cefdinir | 38 | 34 |
| Glimepiride | Glimepiride | 37 | 13 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 21 |
| Cephalexin | Cephalexin | 34 | 33 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | 11 |
| Amoxicillin | Amoxicillin | 32 | 30 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 19 |
| Atenolol | Atenolol | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 12 |
| Topiramate | Topiramate | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 29 |
| Finasteride | Finasteride | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 11 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 24 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 20 |
| Colchicine | Colchicine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 12 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Nystatin | Nystatin | 18 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.80 · 3 records | bioMerieux Inc | BOTOX, FilmArray Torch Module, QULIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error